Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

Exclusion Criteria

• •1. Hypersensitivity to the investigational product or any of its components
• •2. Any other condition causing chronic anemia
• •3. Coagulopathy or unstable anticoagulant dosing during screening
• •4. Any of the following laboratory abnormalities at screening:
• •1. Serum albumin \<35 g/L
• •2. ALT or AST \>3×ULN
• •5. Active infections or carrier status including:
• •* Known HIV infection
• •* Active syphilis
• •* Active HBV infection (HBsAg-positive with HBV DNA \>10³ copies/mL)
• •* Active HCV infection (anti-HCV positive with detectable HCV RNA)
• •6. Acute joint injury with active trauma or infection at screening
• •7. Cognitive impairment or psychiatric disorders,current or history of epilepsy
• •8. Treatment with ESAs (erythropoiesis-stimulating agents) or HIF inhibitors within 30 days prior to dosing
• •9. History of severe thromboembolic events or hematopoietic disorders
• •10. Malignancy history
• •11. Severe cardiovascular diseases including:
• •* Unstable coronary artery disease
• •* Heart failure (NYHA Class III/IV)
• •* Myocardial infarction/stroke 12 .Poorly controlled hypertension
• •13\. Alcohol abuse 14.Pregnancy or lactation 15.Participation in other drug trials within 3 months prior to enrollment 16.Any other condition deemed by the Investigator to compromise subject safety or trial validity